Results 231 to 240 of about 45,588 (281)
Vardenafil in the multidisciplinary management of erectile dysfunction: a narrative review on multidimensional outcomes and clinical integration. [PDF]
World J UrolZhou J, Hu S, Ouyang Y, Kong Y, Liu M.
europepmc +1 more source
Antifibrotic Strategies Targeting Phosphodiesterase-4 in Idiopathic Pulmonary Fibrosis: Molecular Mechanisms and Clinical Translation. [PDF]
Clin PharmacolMa Q +6 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
FR226807: a potent and selective phosphodiesterase type 5 inhibitor
European Journal of Pharmacology, 2001We describe the pharmacological characteristics of a novel phosphodiesterase type 5 inhibitor FR226807, N-(3,4-dimethoxybenzyl)-2-[[(1R)-2-hydroxy-1-methylethyl]amino]-5-nitrobenzamide. FR226807 inhibited phosphodiesterase type 5 isolated from human platelets with an IC(50) value of 1.1 nM. FR226807 also inhibited phosphodiesterase type 6 with an IC(50)
Akira Nagashima +2 more
exaly +3 more sources
Characterization of a novel phosphodiesterase type 5 inhibitor: JNJ-10258859
European Journal of Pharmacology, 2003We have characterized a novel, potent, and selective phosphodiesterase type 5 inhibitor, JNJ-10258859 ((R)-(-)-3-(2,3-dihydro-benzofuran-5-yl)-2-[5-(4-methoxy-phenyl)-pyrimidin-2-yl]-1,2,3,4-tetrahydro-pyrrolo[3,4-b]quinolin-9-one). Its inhibitory effects on phosphodiesterase 1-6 were determined using enzymes partially purified from human tissues.
Yuhong Qiu +2 more
exaly +3 more sources
Phosphodiesterase Type 5 Inhibitors: The Day After
European Urology, 2007Review the literature on phosphodiesterase type 5 inhibitors (PDE5-Is), addressing critical issues in their current and future use, assessing unanswered questions, and identifying research needs.A MEDLINE search was conducted on PDE5-Is, with emphasis on clinical trials and experience, for interpretation and analysis of their present and future role ...
Konstantinos, Hatzimouratidis +1 more
openaire +2 more sources
Phosphodiesterase Type 5 Inhibitors: Unmet Needs
Current Pharmaceutical Design, 2009Erectile dysfunction (ED) has been revolutionized during the last two decades, as several treatment options are available today. Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil) are currently the first choice treatment option for ED by most physicians and patients due to their high efficacy rates and favourable safety ...
K, Hatzimouratidis, D G, Hatzichristou
openaire +2 more sources
Phosphodiesterase type 5 inhibitors for erectile dysfunction
BJU International, 2005This is our first presentation of Great Drug Classes, and we start with a description of phosphodiesterase type 5 inhibitors and their use in erectile dysfunction. This is an in‐depth review of this class of drugs, offering the reader a description of how they work, in which conditions they may be particularly beneficial, and a ...
Culley C, Carson, Tom F, Lue
openaire +2 more sources
Phosphodiesterase type 5 inhibitors and kidney disease
International Urology and Nephrology, 2015Chronic kidney disease (CKD) represents a worldwide health problem. Traditionally, the nephroprotective treatment for CKD aims to slow progression to end-stage renal disease and includes dietary protein restriction, correction of metabolic acidosis, and renin-angiotensin system blockers.
Baris, Afsar +6 more
openaire +2 more sources
Phosphodiesterase Type 5 (PDE5) Inhibitors
2003Publisher Summary In recent years, the field of Phosphodiesterase Type 5 (PDE5) inhibitors has reached a state of maturity. Standard issues in medicinal chemistry, such as potency, selectivity, physico-chemical properties and oral bioavailability, have been successfully addressed with the known PDE5 inhibitors.
Helmut, Haning +2 more
openaire +2 more sources
How to Evaluate the Efficacy of the Phosphodiesterase Type 5 Inhibitors
The Journal of Sexual Medicine, 2012Several methods have been so far proposed to compare the effectiveness of the three available phosphodiesterase type 5 inhibitors (PDE5Is).Two urologists (E.C. and G.B.B.), together with the Controversy's Editor (E.A.J.), with expertise in the area of medical treatment of erectile dysfunction (ED) present the various perspectives on the evaluation of ...
JANNINI, EMMANUELE ANGELO FRANCESCO +3 more
openaire +6 more sources